Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (Weighted Average) (2019 - 2025)

Vivos Therapeutics has reported Shares Outstanding (Weighted Average) over the past 7 years, most recently at $10.3 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 104.66% to $10.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Dec 2025, up 104.66% year-over-year, with the annual reading at $10.3 million for FY2025, 104.66% up from the prior year.
  • Shares Outstanding (Weighted Average) was $10.3 million for Q4 2025 at Vivos Therapeutics, up from $9.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $21.2 billion in Q4 2021 and troughed at $849446.0 in Q3 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $7.6 million (2024), against an average of $3.1 billion.
  • Year-over-year, Shares Outstanding (Weighted Average) skyrocketed 166659.38% in 2021 and then plummeted 100.0% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $21.2 billion in 2021, then plummeted by 100.0% to $920592.0 in 2022, then skyrocketed by 32.46% to $1.2 million in 2023, then soared by 311.67% to $5.0 million in 2024, then soared by 104.66% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Shares Outstanding (Weighted Average) are $10.3 million (Q4 2025), $9.6 million (Q3 2025), and $9.1 million (Q2 2025).